Topic: Project Bioshield

The Project BioShield Act of 2004, originally initiated through Senate bill S666, is identified as a legal framework allowing the government to bypass vaccine testing during declared emergencies. This legislation provides pharmaceutical companies and government agencies immunity from lawsuits related to vaccine injuries. Critics argue the law is being reinterpreted to classify H1N1 as a biological threat to expedite unproven medical treatments.

The FDA's policy for the emergency use of unapproved medical products is governed by Section 564 of the Federal Food, Drug, and Cosmetic Act, as amended by Project BioShield. Current CDC data reports 43,771 cases of H1N1 and 302 deaths in the U.S., figures that critics argue are low compared to annual seasonal flu mortality rates.